JP2018516244A - 肺がんを処置するための方法 - Google Patents

肺がんを処置するための方法 Download PDF

Info

Publication number
JP2018516244A
JP2018516244A JP2017554475A JP2017554475A JP2018516244A JP 2018516244 A JP2018516244 A JP 2018516244A JP 2017554475 A JP2017554475 A JP 2017554475A JP 2017554475 A JP2017554475 A JP 2017554475A JP 2018516244 A JP2018516244 A JP 2018516244A
Authority
JP
Japan
Prior art keywords
fra
antibody
seq
patient
expression level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017554475A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516244A5 (OSRAM
Inventor
ダニエル ジョン オシャネシー，
ダニエル ジョン オシャネシー，
Original Assignee
モーフォテック， インコーポレイテッド
モーフォテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モーフォテック， インコーポレイテッド, モーフォテック， インコーポレイテッド filed Critical モーフォテック， インコーポレイテッド
Publication of JP2018516244A publication Critical patent/JP2018516244A/ja
Publication of JP2018516244A5 publication Critical patent/JP2018516244A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2017554475A 2015-04-17 2016-04-14 肺がんを処置するための方法 Pending JP2018516244A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562149184P 2015-04-17 2015-04-17
US62/149,184 2015-04-17
PCT/US2016/027497 WO2016168440A1 (en) 2015-04-17 2016-04-14 Methods for treating lung cancer

Publications (2)

Publication Number Publication Date
JP2018516244A true JP2018516244A (ja) 2018-06-21
JP2018516244A5 JP2018516244A5 (OSRAM) 2019-03-28

Family

ID=55809240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017554475A Pending JP2018516244A (ja) 2015-04-17 2016-04-14 肺がんを処置するための方法

Country Status (13)

Country Link
US (1) US20180125970A1 (OSRAM)
EP (1) EP3283886B1 (OSRAM)
JP (1) JP2018516244A (OSRAM)
KR (1) KR20170137848A (OSRAM)
CN (1) CN107624071A (OSRAM)
AU (1) AU2016248222A1 (OSRAM)
BR (1) BR112017022320A2 (OSRAM)
CA (1) CA2983126A1 (OSRAM)
IL (1) IL255079A0 (OSRAM)
MX (1) MX2017013390A (OSRAM)
RU (1) RU2718780C9 (OSRAM)
SG (1) SG11201708546UA (OSRAM)
WO (1) WO2016168440A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239910A1 (en) * 2005-04-22 2006-10-26 Morphotek Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
WO2015186823A1 (ja) * 2014-06-06 2015-12-10 協和発酵キリン株式会社 Ｆｏｌｒ１標的薬および葉酸代謝拮抗剤によるがん患者のための治療方法並びに医薬
WO2018098277A1 (en) * 2016-11-23 2018-05-31 Eisai R&D Management Co., Ltd Anti-folate receptor alpha antibodies and uses thereof
SG11202007494TA (en) 2018-03-13 2020-09-29 Phanes Therapeutics Inc Anti-folate receptor 1 antibodies and uses thereof
EA202092964A1 (ru) * 2018-06-18 2021-03-30 Медиммун Лимитед Комбинация ингибиторов lif и антинеопластических средств на основе платины для применения в лечении рака
CN110221052B (zh) * 2019-06-17 2022-09-23 昆山德诺瑞尔生物科技有限公司 Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用
IL314452A (en) * 2022-03-11 2024-09-01 Astrazeneca Ab A scoring method for an anti-frα antibody-drug conjugate therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
US20060239910A1 (en) * 2005-04-22 2006-10-26 Morphotek Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
RU2630608C2 (ru) 2010-11-05 2017-09-11 Морфотек Инк. Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа
CN103998467B (zh) * 2011-07-15 2016-12-14 卫材R&D管理有限公司 抗叶酸受体α抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EXPERT OPIN INVESTIG DRUGS., vol. 24(1), JPN6019047001, January 2015 (2015-01-01), pages 125 - 132, ISSN: 0004165962 *

Also Published As

Publication number Publication date
WO2016168440A1 (en) 2016-10-20
CN107624071A (zh) 2018-01-23
EP3283886A1 (en) 2018-02-21
US20180125970A1 (en) 2018-05-10
RU2718780C9 (ru) 2020-07-08
SG11201708546UA (en) 2017-11-29
MX2017013390A (es) 2018-06-13
AU2016248222A1 (en) 2017-11-09
BR112017022320A2 (pt) 2018-07-24
RU2017136863A (ru) 2019-05-17
EP3283886B1 (en) 2020-01-15
CA2983126A1 (en) 2016-10-20
IL255079A0 (en) 2017-12-31
KR20170137848A (ko) 2017-12-13
RU2017136863A3 (OSRAM) 2019-08-21
RU2718780C2 (ru) 2020-04-14

Similar Documents

Publication Publication Date Title
EP2438442B1 (en) Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
RU2718780C9 (ru) Способы лечения рака легкого
US20190202930A1 (en) Methods for treatment of ovarian cancer
US10221240B2 (en) Methods for treatment of gastric cancer
US20140005059A1 (en) Biomarkers for cancer
US20190154694A1 (en) Detection and treatment of cancer
WO2022154037A1 (ja) がんの予後バイオマーカー
KR20180013878A (ko) 렌바티닙 및 에베로리무스를 포함하는 병용 요법을 위한 생체표지
WO2019064073A1 (en) USE OF CA125 FOR PREDICTING ANTI-MESOTHELIC TREATMENT OF MESOTHELIOMES
CN110546510A (zh) 预后方法和在所述方法中有用的试剂盒

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191202

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191211

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191211

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200623